Literature DB >> 21904895

Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice.

Sara K Olsson1, Markus K Larsson, Sophie Erhardt.   

Abstract

The neuromodulating tryptophan metabolite kynurenic acid (KYNA) is increased in the brain of patients with schizophrenia. In the present study we investigate the spontaneous locomotor activity as well as the locomotor response to d-amphetamine [5 mg/kg, administered intraperitoneal (i.p.)] after increasing endogenous levels of brain KYNA in mice by acute (10 mg/kg, i.p., 60 min) or subchronic (100 mg/kg i.p., twice daily for 6 days) pretreatment with the blood-brain crossing precursor, L: -kynurenine. We found that an acute increase in the brain KYNA levels caused increased corner time and percent peripheral activity but did not change the d-amphetamine-induced locomotor response. In contrast, subchronic elevation of KYNA did not change the spontaneous locomotor activity but produced an exaggerated d-amphetamine-induced hyperlocomotion. These results cohere with clinical studies of patients with schizophrenia, where a potentiated DA release associated with exacerbation of positive symptoms has been observed following d-amphetamine administration. Present results further underscore KYNA as a possible mediator of the aberrant dopaminergic neurotransmission seen in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21904895     DOI: 10.1007/s00702-011-0706-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  54 in total

1.  Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding.

Authors:  Amy C Chess; David J Bucci
Journal:  Behav Brain Res       Date:  2006-04-18       Impact factor: 3.332

2.  Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons--possible involvement of endogenous kynurenic acid.

Authors:  Lilly Schwieler; Sophie Erhardt; Linda Nilsson; Klas Linderholm; Göran Engberg
Journal:  Synapse       Date:  2006-04       Impact factor: 2.562

3.  Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum.

Authors:  Arash Rassoulpour; Hui-Qiu Wu; Sergi Ferre; Robert Schwarcz
Journal:  J Neurochem       Date:  2005-05       Impact factor: 5.372

4.  Pharmacological characterization of alpha-bungarotoxin-sensitive acetylcholine receptors immunoisolated from chick retina: contrasting properties of alpha 7 and alpha 8 subunit-containing subtypes.

Authors:  R Anand; X Peng; J J Ballesta; J Lindstrom
Journal:  Mol Pharmacol       Date:  1993-11       Impact factor: 4.436

5.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

6.  Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus.

Authors:  A H Ganong; C W Cotman
Journal:  J Pharmacol Exp Ther       Date:  1986-01       Impact factor: 4.030

7.  Increased cortical kynurenate content in schizophrenia.

Authors:  R Schwarcz; A Rassoulpour; H Q Wu; D Medoff; C A Tamminga; R C Roberts
Journal:  Biol Psychiatry       Date:  2001-10-01       Impact factor: 13.382

8.  Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis.

Authors:  Klas R Linderholm; Alexandra Andersson; Sara Olsson; Elin Olsson; Ralph Snodgrass; Göran Engberg; Sophie Erhardt
Journal:  Neuropharmacology       Date:  2007-09-20       Impact factor: 5.250

9.  Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?

Authors:  Thomas J Connor; Neasa Starr; Joan B O'Sullivan; Andrew Harkin
Journal:  Neurosci Lett       Date:  2008-06-07       Impact factor: 3.046

10.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.

Authors:  R S Mansbach; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1989-12       Impact factor: 7.853

View more
  12 in total

1.  Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice.

Authors:  M K Larsson; A Faka; M Bhat; S Imbeault; M Goiny; F Orhan; A Oliveros; S Ståhl; X C Liu; D S Choi; K Sandberg; G Engberg; L Schwieler; S Erhardt
Journal:  Neurochem Res       Date:  2016-05-10       Impact factor: 3.996

Review 2.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

3.  Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia.

Authors:  Joshua Chiappelli; Francesca M Notarangelo; Ana Pocivavsek; Marian A R Thomas; Laura M Rowland; Robert Schwarcz; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2018-02-27       Impact factor: 7.853

4.  Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; Francesca M Notarangelo; S Andrea Wijtenburg; Marian A R Thomas; Ana Pocivavsek; Aaron Jones; Krista Wisner; Peter Kochunov; Robert Schwarcz; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2018-04-18       Impact factor: 7.853

5.  Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment--role of brain kynurenic acid.

Authors:  Xi-Cong Liu; Maria Holtze; Susan B Powell; Niccolò Terrando; Markus K Larsson; Anna Persson; Sara K Olsson; Funda Orhan; Magdalena Kegel; Linnea Asp; Michel Goiny; Lilly Schwieler; Göran Engberg; Håkan Karlsson; Sophie Erhardt
Journal:  Brain Behav Immun       Date:  2013-10-17       Impact factor: 7.217

Review 6.  The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

7.  Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders.

Authors:  Sophie Erhardt; Ana Pocivavsek; Mariaelena Repici; Xi-Cong Liu; Sophie Imbeault; Daniel C Maddison; Marian A R Thomas; Joshua L Smalley; Markus K Larsson; Paul J Muchowski; Flaviano Giorgini; Robert Schwarcz
Journal:  Biol Psychiatry       Date:  2016-12-16       Impact factor: 13.382

8.  Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice.

Authors:  Dániel Varga; Judit Herédi; Zita Kánvási; Marian Ruszka; Zsolt Kis; Etsuro Ono; Naoki Iwamori; Tokuko Iwamori; Hiroki Takakuwa; László Vécsei; József Toldi; Levente Gellért
Journal:  Front Behav Neurosci       Date:  2015-06-16       Impact factor: 3.558

9.  Chronic Antipsychotic Treatment in the Rat - Effects on Brain Interleukin-8 and Kynurenic Acid.

Authors:  Markus K Larsson; Lilly Schwieler; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Int J Tryptophan Res       Date:  2015-09-20

10.  Imbalanced kynurenine pathway in schizophrenia.

Authors:  Magdalena E Kegel; Maria Bhat; Elisabeth Skogh; Martin Samuelsson; Kristina Lundberg; Marja-Liisa Dahl; Carl Sellgren; Lilly Schwieler; Göran Engberg; Ina Schuppe-Koistinen; Sophie Erhardt
Journal:  Int J Tryptophan Res       Date:  2014-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.